

Curriculum Vitae

Personal information **Roeland Martijn Van der Plas**

Work experience

1. Employer: CBG_MEB
 - Start date: 062011
 - End date:
 - Position: Senior Assessor
 - Activities: Assessment of dossiers (new applications and variations); contributions to guideline development.
 - Country: Netherlands
2. Employer: RIVM
 - Start date: 062000
 - End date: 052011
 - Position: (Senior) assessor
 - Activities: Assessment of dossiers (new applications and variations); contributions to guideline development, for CBG_MEB. Supporting roles in other research and OCABR activities at RIVM.
 - Country: Netherlands
3. Employer: Chiron BV/ Parexel Mirai
 - Start date: 091999
 - End date: 052000
 - Position: Data manager
 - Activities: Data management in support of clinical trials
 - Country: Netherlands
4. Employer: NWO _ Nederlandse organisatie voor Wetenschappelijk Onderzoek
 - Start date: 071994
 - End date: 121998
 - Position: Onderzoeker in Opleiding (research assistant)
 - Activities: Performing scientific research, resulting in a Ph. D thesis.
 - Country: Netherlands
5. Employer: Vrije Universiteit Amsterdam
 - Start date: 011992
 - End date: 031992
 - Position: Student assistant (teaching assistant)
 - Activities:
 - Country: Netherlands

Education and training

1. Subject: Universiteit Utrecht
 - Start date: 071994
 - End date: 061999
 - Qualification: Ph. D.
 - Organisation: Resulted in Ph. D Thesis: 'The first step of hemostasis: Structure and function of multimeric von Willebrand Factor'
 - Country: Netherlands
2. Subject: Vrije Universiteit Amsterdam
 - Start date: 081988
 - End date: 061994
 - Qualification: Doctorandus
 - Organisation: Degree equivalent to Master of Science in Chemistry/Pharmacology. Major in 'Molecular Pharmacology'.
 - Country: Netherlands

Additional information

Publications

De Groot MJ, Van der Aar EM, Nieuwenhuizen PJ, Van der Plas RM, Donne Op den Kelder GM, Commandeur IN, Vermeulen NP: A predictive substrate model for rat glutathione S_transferase 4_4. Chem Res Toxicol 1995; 8 649_658

Bast A, Van der Plas RM, van den Berg H, Haenen GR: Beta carotene as antioxidant. Eur J Clin Nutr 1996; 50 Suppl 3:S54_S56

Huizinga EG, Van der Plas RM. Kroon J, Sixma JJ, Gros P: Crystal structure of the A3 domain of human von Willebrand factor: implications for collagen binding. Structure 1997; 5 1147_1156

Sixma JJ, Van Zanten GH, Huizinga EG, Van der Plas RM, Verkley M, Wu YP, Gros P, De Groot PG: Platelet adhesion to collagen: An update. Thromb Haemostas 1997; 78 434_438

Van der Plas RM, Schiphorst ME, Huizinga EG, Hené RJ, Verdonck LF, Sixma JJ, Fijnheer R: Von Willebrand proteolysis is deficient in classic, but not in bone marrow transplantation associated thrombotic thrombocytopenic purpura. Blood 1999; 94(10) 3611_2

Vanhoorelbeke K, van der Plas RM, Vandecasteele O, Vauterin S, Huizinga EG, Sixma JJ, Deckmyn H: Sequence alignment between vWF and peptides inhibiting the vWF_collagen interaction does not result in the identification of a collagen_binding site in vWF. *Thromb Haemost* 2000; 84(4) 62 1_5

Van der Plas RM, Gomes L, Marquart JA, Vink T, Meijers JC, de Groot PG, Sixma JJ, Huizinga EG: Binding of von Willebrand factor to collagen type III: role of specific amino acids in the collagen binding domain of vWF and effects of neighboring domains. *Thromb Haemost* 2000; 84(6) 1005_11

Christian K Schneider, John J Borg, Falk Ehmann, Niklas Ekman, Esa Heinonen, Kowid Ho, Marcel H Hoefnagel, Roeland Martijn van der Plas, Sol Ruiz, Antonius J van der Stappen, Robin Thorpe, Klara Tiitso, Asterios S Tsiftoglou, Camille Vleminckx, Guenter Waxenecker, Mats Welin, Martina Weise, Jean_Hugues Trouvin: In support of the European Union biosimilar framework. *Nature Biotechnology* 2012; 30 745–748

Van der Plas RM, Van Zwieten BJ, Jongen PM, Hoefnagel MH: The EU regulatory approach to generics and biosimilars is essentially similar. *Generics and Biosimilars Initiative Journal (GaBI Journal)*. 2015;4(1):9_10

Van der Plas RM, Hoefnagel MH, Hillege HL, Roes CB: Pragmatic rules for comparability of biological medicinal products. *Biologicals*. 2020 Jan 63:97_100

Alsamil AM, Giezen TJ, Egberts TC, Leufkens HG, Vulto AG, van der Plas MR, Gardarsdottir H. Reporting of quality attributes in scientific publications presenting biosimilarity assessments of (intended) biosimilars: a systematic literature review. *Eur J Pharm Sci*. 2020 Nov 1;154:105501. doi: 10.1016/j.ejps.2020.105501. Epub 2020 Jul 30. PMID: 32739253.

Projects

Memberships

Member of scientific planning committee annual PDA workshop on monoclonal antibodies (2013-2019); in 2015 and 2018 as co-chair of the meeting

Member of scientific planning committee CASSS CMC forum (2018_present); in 2018/19 and 2024 as co-chair of the meeting

Member of EDQM/Ph. Eur MAB WP (since 2016)

Member of EDQM/Ph. Eur group 6B (since 2020)

Other Relevant Information

Acting as 'guest teacher' at Utrecht University (1-2 times annually).